Responses
Clinical/translational cancer immunotherapy
Original research
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.